Portfolio Lab

Zenas BioPharma, Inc.

  • Stock
  • Ticker ZBIO
  • Nasdaq

Health care · Pharmaceuticals · USA

$23.85 −4.75%
Close of 20 Nov 2026
Open in backtest

Performance, volatility and drawdowns of Zenas BioPharma, Inc. since 09/2024, with distributions reinvested and calculated in US dollars. As of 20 Nov 2026.

Performance

ZBIOGlobal equities (VT)

$10,000 grew to $7,632. Global equities (VT): $10,273.

Distributions reinvested, before taxes and brokerage costs. Dashed: Global equities (VT) for comparison.

Declines from the peak

Lowest point −75.0% in 01/2025, measured from the peak in 10/2024. It took 12 months to get back to the old peak.

1-year return
−31.5%
Return p.a. since 09/2024
+13.3%
Volatility p.a.
100.1%
Largest decline
−75.0%

Financial statements

Amounts in $ millions from filings with the SEC, earnings per share in $; fourth quarter and quarterly cash flow derived from year-to-date figures

Quarter end12/202403/202506/202509/202512/202503/202606/202609/2026
Income statement
Revenue5.0100.00.00.0–1.010
Operating income-56-37-55-53-238-77-108-103
EBITDA-56-37-55-53-238-77-108-103
Net income-53-34-52-51-240-81-111-109
Earnings per share16.94-0.80-1.25-1.22-5.17-1.46-1.77-1.65
Balance sheet
Total assets370334293322384748702675
Liabilities584953126141412455463
Equity312284240196242336247212
Cash32019744116111500197178
Long-term debt–––7379–––
Cash flow
Operating cash flow-39-37-42-41-52-75-57-58
Capital expenditure-0.10.00.00.00.00.00.00.0
Free cash flow-39-37-42-41-52-75-57-58

Value it:DCF calculatorMultiples calculator

Annual returns

* partial year.

Quarterly reports

Filing date with the SEC and earnings per share of the quarter

DayEarnings per share
5 Nov 2026−$1.65
13 Aug 2026−$1.77
13 May 2026−$1.46
16 Mar 2026−$5.17
12 Nov 2025−$1.22
12 Aug 2025−$1.25
15 May 2025−$0.80
11 Mar 2025$16.94
12 Nov 2024$1.96

Key metrics

Metrics of 15 Nov 2026; P/E, P/B, P/S, market cap and dividend yield at the last close.

Valuation

Market cap
€1.5bn
Market cap in trading currency
$1.62bn
Enterprise value
$1.03bn
P/E
–
P/S
–
P/B
7.62
EV/Sales
–
EV/EBITDA
–
Earnings yield
–
FCF yield
-15.0%

Results (last four quarters)

Revenue
–
Gross profit
–
EBITDA
−$526m
Net income
−$542m
Earnings per share
−$10.05
Revenue per share
–
Revenue growth
–
Earnings growth
–

Profitability

Gross margin
–
Operating margin
–
Net margin
–
Return on equity
-265.1%
Return on assets
-80.2%

Balance sheet and cash flow

Cash
$585m
Cash per share
$8.63
Financial debt
–
Debt/equity %
–
Current ratio
9.42
Book value per share
$3.13
Operating cash flow
−$243m
Free cash flow
−$243m

Dividend

Dividend yield
0.00%
Dividend (12 months)
$0.00
Yield (12 months)
0.00%
Payout ratio
–
Ex-dividend date
–

Shares and trading

Shares outstanding
67.8m
Volume
576,521
Avg. volume 3 months
647,934
Relative volume
1.0

Price and technicals

Price
$23.85
1 day
−4.8%
52-week high
$43.17
52-week low
$15.20
Distance to 52-week high
−44.8%
Distance to 52-week low
+56.9%
Distance to 50-day line
−14.8%
Distance to 200-day line
−6.5%
RSI (14)
33
Volatility 1M
62.7%

Performance

1 week
−14.9%
1 month
−15.5%
3 months
−24.6%
6 months
+25.7%
YTD
−34.3%
1 year
−35.8%

Dates

Fiscal year end
31 Dec 2025
Most recent quarter
30 Sep 2026

Frequently asked questions

How has ZBIO performed since 09/2024?

$10,000 grew to $13,140 by 20 Nov 2026, which is +13.3% per year. Distributions are reinvested; taxes and brokerage costs are not deducted.

How volatile is ZBIO?

Volatility was 100.1% per year, measured on monthly returns. The largest decline from a peak was −75.0%, with the low in 01/2025.

How does ZBIO compare with a broad equity ETF?

Over the same period Global equities (VT) returned +11.4% per year at 13.2% volatility, ZBIO returned +13.3% at 100.1%. The correlation of monthly returns was 0.02; 1 would mean they moved in lockstep.

Which currency are the figures in?

In US dollars, the currency of the US listing.

Not investment advice. Metrics and financial statements calculated from the company's mandatory filings with the SEC, without guarantee; amounts in US dollars.

Reference data of securities: source ESMA (FIRDS reference data) and SEC (EDGAR).

Not investment advice: results in Portfolio Lab are model calculations based on historical data and your inputs. Past performance is not a reliable indicator of future results.

Zenas BioPharma, Inc. (ZBIO): Return and risk